Navigation Links
Ampio Pharmaceuticals, Inc. States that its Policy is Not to Comment on Unusual Market Activity
Date:10/25/2013

GREENWOOD VILLAGE, Colo., Oct. 25, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it was contacted by the New York Stock Exchange in light of unusual market activity in the Company's common stock on Thursday, October 24, 2013. In accordance with the New York Stock Exchange's usual practice, the Company announced that its policy is not to comment on unusual market activity; however, the management did summarize significant milestones achieved over the past ten weeks including:

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

  • Positive results for Ampion in osteoarthritis of the knee clinical trial
  • $25 million financing
  • Positive summary data from Luoxis Diagnostics' study of traumatic brain injury patients and issuance of company's third US patent for its oxidation-reduction potential diagnostic platform
  • Positive results from Independent Panel Review of the interim analysis of the Optina trial for diabetic macular edema

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the completion, timing and size of the registered direct offering, as well as risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
Email: rgiles@ampiopharma.com


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
2. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
3. Ampio Pharmaceuticals, Inc. Announces $25 Million Financing
4. Astellas to Host Executive Womens Day at 2013 TOUR Championship by Coca-Cola
5. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
6. Levine Leichtman Acquires Champion Manufacturing
7. Pro Athletes Team Up to Champion Gout Awareness
8. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
9. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
10. Ampio Pharmaceuticals to List on the NYSE MKT
11. Ampio Pharmaceuticals Provides Clinical Updates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... Argos ... industry expansion into the healthcare sector during the second quarter of 2019. Three ... cycle management join a strong client list in managing and mitigating third-party ...
(Date:7/17/2019)... ... July 16, 2019 , ... Steven C. Bilt, Chief ... driver of business performance in the dental industry during a panel discussion at Dykema’s ... July 11th at the Omni Dallas Hotel in Dallas, Texas. , Bilt co-founded Smile ...
(Date:7/17/2019)... NEW YORK (PRWEB) , ... ... ... , an industry-leading resource for finding quality assisted living options, has announced ... 26 top facilities based on healthcare services, amenities, resident satisfaction, affordability and ...
Breaking Medicine Technology:
(Date:7/13/2019)... ... 2019 , ... The American Med Spa Association (AmSpa) has released the 2019 ... aesthetic and medical spa professionals understand the realities of the industry and make better, ... two years since AmSpa released the 2017 Medical Spa State of the Industry Report ...
(Date:7/12/2019)... ... 2019 , ... Rebecca Baxt, M.D., F.A.A.D. and Saida Baxt, M.D., F.A.A.D. of ... in Paramus, BAXT CosMedical is a renowned facility that believes in honest consultations and ... past 45 years. , NJ Top Docs, Dr. Rebecca Baxt and Dr. Saida Baxt ...
(Date:7/11/2019)... BETHESDA, Md. (PRWEB) , ... July 11, 2019 ... ... announced new knowledge tools and educational resources with a range of features ... their Members across the global pharmaceutical industry in manufacturing quality medicines for patients ...
(Date:7/10/2019)... ... 10, 2019 , ... Foggiare --the first and only U.S. company to ... and wellness technology. Developed by Sauna Italia , an Italian manufacturer of advanced ... success in over 180 locations in Europe and Asia. Slim-Up is scientifically proven to ...
(Date:7/10/2019)... (PRWEB) , ... July 10, 2019 , ... HMP, a ... an official partner of the Oncology Clinical Pathways Congress, taking place October 11-13, 2019 ... Journal of Clinical Pathways and focuses on the expansion of clinical pathways as a ...
Breaking Medicine News(10 mins):